UA107557C2 - Композиція антитіла офатумумабу - Google Patents

Композиція антитіла офатумумабу

Info

Publication number: UA107557C2
Authority: UA; Ukraine
Prior art keywords: ofatumumab; antibody composition; composition; ofatumumab antibody; antibodies
Prior art date: 2007-07-06

Application number

UAA201001165A

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-06

Filing date

2008-03-07

Publication date

2015-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40228991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA107557(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-03-07 Application filed filed Critical

2015-01-26 Publication of UA107557C2 publication Critical patent/UA107557C2/ru

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychiatry (AREA)
Tropical Medicine & Parasitology (AREA)

UAA201001165A 2007-07-06 2008-03-07 Композиція антитіла офатумумабу UA107557C2 (xx)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US94822007P	2007-07-06	2007-07-06
PCT/US2008/069125 WO2009009407A1 (en)	2007-07-06	2008-07-03	Antibody formulations

Publications (1)

Publication Number	Publication Date
UA107557C2 true UA107557C2 (xx)	2015-01-26

Family

ID=40228991

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA201001165A UA107557C2 (xx)	2007-07-06	2008-03-07	Композиція антитіла офатумумабу

Country Status (38)

Country	Link
US (2)	US20110020328A1 (ru)
EP (2)	EP2170388B1 (ru)
JP (1)	JP5529017B2 (ru)
KR (2)	KR101670454B1 (ru)
CN (1)	CN101820912B (ru)
AR (2)	AR067455A1 (ru)
AU (1)	AU2008275278B2 (ru)
BR (2)	BRPI0814003B1 (ru)
CA (1)	CA2692681C (ru)
CL (1)	CL2008001984A1 (ru)
CO (1)	CO6270340A2 (ru)
CR (1)	CR11249A (ru)
CY (3)	CY1118419T1 (ru)
DK (2)	DK2889310T3 (ru)
DO (1)	DOP2010000001A (ru)
EA (1)	EA017994B1 (ru)
ES (2)	ES2610821T3 (ru)
FR (1)	FR21C1040I1 (ru)
HR (2)	HRP20170033T1 (ru)
HU (3)	HUE038501T2 (ru)
IL (1)	IL202950A (ru)
JO (1)	JO3219B1 (ru)
LT (3)	LT2170388T (ru)
MA (1)	MA31471B1 (ru)
MX (1)	MX2010000017A (ru)
MY (1)	MY210424A (ru)
NO (2)	NO2889310T3 (ru)
NZ (1)	NZ582250A (ru)
PE (1)	PE20090738A1 (ru)
PL (2)	PL2170388T3 (ru)
PT (2)	PT2889310T (ru)
SI (2)	SI2170388T1 (ru)
TR (1)	TR201802928T4 (ru)
TW (2)	TWI515204B (ru)
UA (1)	UA107557C2 (ru)
UY (1)	UY31210A1 (ru)
WO (1)	WO2009009407A1 (ru)
ZA (1)	ZA200909107B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160279239A1 (en)	2011-05-02	2016-09-29	Immunomedics, Inc.	Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en)	2011-05-02	2016-12-08	Immunomedics, Inc.	Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations
WO2011104381A2 (en)	2010-02-26	2011-09-01	Novo Nordisk A/S	Stable antibody containing compositions
SG183443A1 (en)	2010-03-01	2012-09-27	Bayer Healthcare Llc	Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
CA2800188A1 (en)	2010-05-28	2011-12-01	Novo Nordisk A/S	Stable multi-dose compositions comprising an antibody and a preservative
US20140044727A1 (en) *	2011-04-07	2014-02-13	Glaxosmithkline Llc	Formulations with reduced viscosity
UA116189C2 (uk)	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR101875155B1 (ko) *	2011-05-02	2018-07-09	밀레니엄 파머슈티컬스 인코퍼레이티드	항-α4β7 항체에 대한 제형
JP6024025B2 (ja)	2011-05-02	2016-11-09	イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ，Ｉｎｃ．	少容量投与用のアロタイプ選択抗体の限外濾過濃縮
UY34105A (es)	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
EP2968083B1 (en) *	2013-03-12	2021-09-22	Primal Therapies, Inc.	Dental composition comprising chelator and base
EP2805730A1 (en) *	2013-05-21	2014-11-26	Bergen Teknologioverforing AS	Nitric oxide donor for the treatment of chronic fatigue syndrome
WO2015162504A1 (en)	2014-04-23	2015-10-29	Novartis Ag	Novel dosing and uses of ofatumumab
WO2016189491A1 (en) *	2015-05-28	2016-12-01	Glaxosmithkline Intellectual Property Development Limited	Novel formulation
AU2017213775A1 (en) *	2016-02-03	2018-08-16	Outlook Therapeutics, Inc.	Buffer formulations for enhanced antibody stability
CN109641965A (zh) *	2016-08-15	2019-04-16	诺华股份有限公司	使用奥法木单抗治疗多发性硬化的方案和方法
JPWO2018179138A1 (ja) *	2017-03-29	2020-02-06	持田製薬株式会社	抗体含有液体製剤
WO2018187074A1 (en)	2017-04-03	2018-10-11	Immunomedics, Inc.	Subcutaneous administration of antibody-drug conjugates for cancer therapy
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en)	2017-05-02	2019-11-28	Merck Sharp & Dohme	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
US11513046B2 (en) *	2018-02-09	2022-11-29	Championx Usa Inc.	Flowability testing systems and methods
EP3876990A4 (en)	2018-11-07	2023-09-06	Merck Sharp & Dohme LLC	CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES
TWI874341B (zh)	2018-12-18	2025-03-01	美商健生生物科技公司	產生異二聚體抗體之方法
CN118403156A (zh)	2019-09-11	2024-07-30	诺华股份有限公司	通过转换疗法治疗rms
US20220389109A1 (en)	2019-09-11	2022-12-08	Novartis Ag	Management of conditions other than multiple sclerosis in ofatumumab-treated patients
CN112675126A (zh) *	2019-10-18	2021-04-20	百奥泰生物制药股份有限公司	抗cd20抗体制剂及其应用
IL296701A (en)	2020-04-09	2022-11-01	Novartis Ag	Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serum
US20230227570A1 (en)	2020-05-08	2023-07-20	Genmab A/S	Bispecific antibodies against cd3 and cd20
JP7057954B2 (ja) *	2020-09-03	2022-04-21	国立大学法人大阪大学	改善された保存安定性を有するタンパク質含有液体製剤
WO2022219057A1 (en)	2021-04-14	2022-10-20	Novartis Ag	Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en)	2021-08-16	2024-10-17	Novartis Ag	Ofatumumab for treating pediatric ms
KR20230150203A (ko) *	2022-04-20	2023-10-30	주식회사 알토스바이오로직스	오크렐리주맙(Ocrelizumab)을 포함하는 약학적 조성물과 그의 용도
CN116712390B (zh) *	2023-08-04	2023-11-14	上海览屹医药科技有限公司	一种高浓度高稳定性的抗体制剂及其制备方法
WO2025037335A1 (en) *	2023-08-12	2025-02-20	Dr. Reddy's Laboratories Limited	Formulations of anti-cd20 antibody

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4816401A (en) *	1985-09-09	1989-03-28	University Of Rochester	Serum free cell culture medium
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
DK0999853T3 (da) *	1997-06-13	2003-04-22	Genentech Inc	Stabiliseret antostofformulering
CN100389821C (zh) *	1999-10-04	2008-05-28	希龙公司	稳定化的含多肽的液体药物组合物
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
CN100522999C (zh)	2002-02-14	2009-08-05	免疫医疗公司	抗cd20抗体及其融合蛋白和使用方法
US20030180287A1 (en) *	2002-02-27	2003-09-25	Immunex Corporation	Polypeptide formulation
CN1671741A (zh) *	2002-06-21	2005-09-21	拜奥根Idec公司	浓缩抗体的缓冲剂制剂及其使用方法
WO2004035607A2 (en) *	2002-10-17	2004-04-29	Genmab A/S	Human monoclonal antibodies against cd20
ES2373947T3 (es) *	2002-12-16	2012-02-10	Genmab A/S	Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
US8084582B2 (en) *	2003-03-03	2011-12-27	Xencor, Inc.	Optimized anti-CD20 monoclonal antibodies having Fc variants
AR044388A1 (es)	2003-05-20	2005-09-07	Applied Molecular Evolution	Moleculas de union a cd20
EP1740946B1 (en)	2004-04-20	2013-11-06	Genmab A/S	Human monoclonal antibodies against cd20
DOP2006000029A (es) *	2005-02-07	2006-08-15	Genentech Inc	Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
DK1865986T3 (en) *	2005-03-08	2016-04-11	Pfizer Prod Inc	The anti-CTLA-4 antibody compositions
JP2009510046A (ja) *	2005-09-30	2009-03-12	メドイミューン・リミテッド	インターロイキン−１３抗体組成物
US20100189721A1 (en) *	2007-07-06	2010-07-29	Smithkline Beecham Corporation	Antibody formulations
UA107557C2 (xx) *	2007-07-06	2015-01-26		Композиція антитіла офатумумабу

2008
- 2008-03-07 UA UAA201001165A patent/UA107557C2/ru unknown
- 2008-07-03 HU HUE15155712A patent/HUE038501T2/hu unknown
- 2008-07-03 MY MYPI2010000010A patent/MY210424A/en unknown
- 2008-07-03 KR KR1020157019741A patent/KR101670454B1/ko active Active
- 2008-07-03 EP EP08781323.4A patent/EP2170388B1/en active Active
- 2008-07-03 US US12/667,890 patent/US20110020328A1/en not_active Abandoned
- 2008-07-03 BR BRPI0814003-0A patent/BRPI0814003B1/pt active IP Right Grant
- 2008-07-03 EA EA201070105A patent/EA017994B1/ru not_active IP Right Cessation
- 2008-07-03 MX MX2010000017A patent/MX2010000017A/es active IP Right Grant
- 2008-07-03 KR KR1020107000148A patent/KR20100038092A/ko not_active Withdrawn
- 2008-07-03 PL PL08781323T patent/PL2170388T3/pl unknown
- 2008-07-03 HR HRP20170033TT patent/HRP20170033T1/hr unknown
- 2008-07-03 DK DK15155712.1T patent/DK2889310T3/en active
- 2008-07-03 BR BR122020026978-2A patent/BR122020026978B1/pt active IP Right Grant
- 2008-07-03 SI SI200831738A patent/SI2170388T1/sl unknown
- 2008-07-03 SI SI200831928T patent/SI2889310T1/en unknown
- 2008-07-03 LT LTEP08781323.4T patent/LT2170388T/lt unknown
- 2008-07-03 NZ NZ582250A patent/NZ582250A/en unknown
- 2008-07-03 JO JOP/2008/0312A patent/JO3219B1/ar active
- 2008-07-03 CN CN200880105866.1A patent/CN101820912B/zh active Active
- 2008-07-03 JP JP2010516158A patent/JP5529017B2/ja active Active
- 2008-07-03 WO PCT/US2008/069125 patent/WO2009009407A1/en not_active Ceased
- 2008-07-03 ES ES08781323.4T patent/ES2610821T3/es active Active
- 2008-07-03 PT PT151557121T patent/PT2889310T/pt unknown
- 2008-07-03 CA CA2692681A patent/CA2692681C/en active Active
- 2008-07-03 PT PT87813234T patent/PT2170388T/pt unknown
- 2008-07-03 LT LTEP15155712.1T patent/LT2889310T/lt unknown
- 2008-07-03 EP EP15155712.1A patent/EP2889310B1/en active Active
- 2008-07-03 DK DK08781323.4T patent/DK2170388T3/en active
- 2008-07-03 HU HUE08781323A patent/HUE031288T2/hu unknown
- 2008-07-03 ES ES15155712.1T patent/ES2663504T3/es active Active
- 2008-07-03 NO NO15155712A patent/NO2889310T3/no unknown
- 2008-07-03 PL PL15155712T patent/PL2889310T3/pl unknown
- 2008-07-03 AU AU2008275278A patent/AU2008275278B2/en active Active
- 2008-07-03 TR TR2018/02928T patent/TR201802928T4/tr unknown
- 2008-07-04 TW TW097125246A patent/TWI515204B/zh active
- 2008-07-04 TW TW104128324A patent/TWI612060B/zh active
- 2008-07-04 UY UY31210A patent/UY31210A1/es not_active Application Discontinuation
- 2008-07-04 AR ARP080102910A patent/AR067455A1/es unknown
- 2008-07-04 CL CL2008001984A patent/CL2008001984A1/es unknown
- 2008-07-04 PE PE2008001136A patent/PE20090738A1/es active IP Right Grant
2009
- 2009-12-21 ZA ZA2009/09107A patent/ZA200909107B/en unknown
- 2009-12-24 IL IL202950A patent/IL202950A/en active IP Right Grant
- 2009-12-30 MA MA32460A patent/MA31471B1/fr unknown
- 2009-12-30 CO CO09149371A patent/CO6270340A2/es active IP Right Grant
2010
- 2010-01-05 DO DO2010000001A patent/DOP2010000001A/es unknown
- 2010-02-02 CR CR11249A patent/CR11249A/es unknown
2015
- 2015-02-19 US US14/625,881 patent/US20150158951A1/en not_active Abandoned
2017
- 2017-01-12 CY CY20171100043T patent/CY1118419T1/el unknown
- 2017-08-29 AR ARP170102392A patent/AR109461A2/es not_active Application Discontinuation
2018
- 2018-03-14 HR HRP20180440TT patent/HRP20180440T1/hr unknown
- 2018-03-20 CY CY20181100325T patent/CY1120047T1/el unknown
2021
- 2021-09-13 NO NO2021036C patent/NO2021036I1/no unknown
- 2021-09-14 FR FR21C1040C patent/FR21C1040I1/fr active Active
- 2021-09-14 CY CY2021027C patent/CY2021027I2/el unknown
- 2021-09-15 HU HUS2100038C patent/HUS2100038I1/hu unknown
- 2021-09-15 LT LTPA2021520C patent/LTPA2021520I1/lt unknown

Also Published As

Publication number	Publication date
CN101820912A (zh)	2010-09-01
DOP2010000001A (es)	2010-01-31
CY2021027I1 (el)	2021-12-31
DK2889310T3 (en)	2018-03-26
HUE038501T2 (hu)	2018-10-29
CN101820912B (zh)	2014-03-12
CY1118419T1 (el)	2017-06-28
TWI515204B (zh)	2016-01-01
NO2889310T3 (ru)	2018-05-19
CA2692681C (en)	2018-12-04
JO3219B1 (ar)	2018-03-08
TWI612060B (zh)	2018-01-21
AR109461A2 (es)	2018-12-12
ES2610821T3 (es)	2017-05-03
DK2170388T3 (en)	2017-01-16
TW200914466A (en)	2009-04-01
IL202950A (en)	2014-05-28
JP2011526880A (ja)	2011-10-20
LT2889310T (lt)	2018-03-26
CA2692681A1 (en)	2009-01-15
JP5529017B2 (ja)	2014-06-25
HRP20180440T1 (hr)	2018-04-20
FR21C1040I1 (fr)	2021-11-19
CR11249A (es)	2010-03-08
CL2008001984A1 (es)	2009-01-09
KR20150088335A (ko)	2015-07-31
AU2008275278B2 (en)	2011-04-14
EP2889310B1 (en)	2017-12-20
MX2010000017A (es)	2010-04-07
TR201802928T4 (tr)	2018-03-21
EP2170388A4 (en)	2011-07-06
BRPI0814003B1 (pt)	2021-06-15
PE20090738A1 (es)	2009-07-18
MA31471B1 (fr)	2010-06-01
EA201070105A1 (ru)	2010-08-30
BRPI0814003A2 (pt)	2015-02-03
CY2021027I2 (el)	2021-12-31
PT2170388T (pt)	2017-01-04
PT2889310T (pt)	2018-03-26
HUE031288T2 (hu)	2017-06-28
IL202950A0 (en)	2011-08-01
KR20100038092A (ko)	2010-04-12
CY1120047T1 (el)	2018-12-12
CO6270340A2 (es)	2011-04-20
HK1141979A1 (zh)	2010-11-26
MY210424A (en)	2025-09-22
EP2170388A1 (en)	2010-04-07
UY31210A1 (es)	2009-01-30
US20150158951A1 (en)	2015-06-11
WO2009009407A1 (en)	2009-01-15
KR101670454B1 (ko)	2016-10-31
SI2170388T1 (sl)	2017-01-31
EA017994B1 (ru)	2013-04-30
EP2170388B1 (en)	2016-10-12
SI2889310T1 (en)	2018-04-30
HRP20170033T1 (hr)	2017-03-24
LT2170388T (lt)	2017-01-10
AR067455A1 (es)	2009-10-14
PL2889310T3 (pl)	2018-06-29
LTPA2021520I1 (ru)	2021-10-11
EP2889310A1 (en)	2015-07-01
US20110020328A1 (en)	2011-01-27
ES2663504T3 (es)	2018-04-13
HK1207652A1 (en)	2016-02-19
ZA200909107B (en)	2012-12-27
HUS2100038I1 (hu)	2021-10-28
NZ582250A (en)	2012-04-27
BR122020026978B1 (pt)	2021-09-28
NO2021036I1 (no)	2021-09-13
AU2008275278A1 (en)	2009-01-15
TW201623334A (zh)	2016-07-01
PL2170388T3 (pl)	2017-06-30

Publication	Publication Date	Title
UA107557C2 (xx)	2015-01-26	Композиція антитіла офатумумабу
EA200801460A1 (ru)	2009-02-27	Рекомбинантные моновалентные антитела и способы их получения
AR116860A2 (es)	2021-06-23	Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
JP2010529999A5 (ru)	2011-07-28
NZ602054A (en)	2014-10-31	Anti-nerve growth factor (ngf) antibody compositions
NZ595526A (en)	2013-03-28	Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
GT200900167A (es)	2011-08-08	Anticuerpos humanos contra el ligando 4 de tipo delta humano.
UA122478C2 (uk)	2020-11-25	Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1
MA30531B1 (fr)	2009-06-01	Anticorps anti-dll4 et leurs procedes d'utilisation
GT200500298A (es)	2006-05-08	Formulaciones de anticuerpos
NO20083895L (no)	2008-10-24	Anti-IGF-1R human monoklonalantibody formulering
UA115648C2 (uk)	2017-12-11	Доставка терапевтичних агентів до цнс
EP2121008A4 (en)	2010-03-31	USE OF MONOCLONAL ANTIBODY 8H9
NZ627859A (en)	2015-09-25	Stabilized formulations containing anti-ang2 antibodies
MA30497B1 (fr)	2009-06-01	Anticorps et immunco-conjugues, et leurs utilisations.
EA200601670A1 (ru)	2007-02-27	Конъюгаты гидроксиалкилкрахмала и белка
ATE552276T1 (de)	2012-04-15	Modifizierter anti-cd52-antikörper
EA200870193A1 (ru)	2009-02-27	Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EP2185197A4 (en)	2011-11-23	NEW CELL FACTORY SOLUTION COMPOSITIONS
MA34172B1 (fr)	2013-04-03	Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
JP2010522208A5 (ru)	2011-04-28
SG10201405377XA (en)	2014-12-30	Compositions and methods for antibodies targeting complement protein c5
UA106194C2 (ru)	2014-08-11	Диагностика и лечение рака с применением антитела к ereg
NO20091509L (no)	2009-05-28	Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
PA8782201A1 (es)	2009-02-09	Anticuerpo humanizados contra el globulómero ab(20-42) y sus usos